Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3610-3616

  Jansson, Agneta ^a   Delander, Lovisa ^a   Gunnarsson, Cecilia ^a   Fornander, Tommy ^b   Skoog, Lambert ^b   Nordenskjöld, Bo ^a   Stål, Olle ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 1; TESTOSTERONE 17BETA DEHYDROGENASE 2; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

17-HYDROXYSTEROID DEHYDROGENASES; BLOTTING, WESTERN; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 66149186856     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2599     Document Type: Article

References (25)

1. Gunnarsson C, Hellqvist E, Stal O. 17β-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br J Cancer 2005;92:547-552 (Pubitemid 40395536)
2. Gunnarsson C, Olsson BM, Stal O. Abnormal expression of 17β-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res 2001;61:8448-8451 (Pubitemid 33131123)
3. Luu-The V, Tremblay P, Labrie F. Characterization of type 12 17β-hydroxysteroid dehydrogenase, an isoform of type 3 17β- hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol 2006;20:437-443 (Pubitemid 43152516)
4. Miettinen M, Mustonen M, Poutanen M, et al. 17β-Hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Res Treat 1999;57:175-182 (Pubitemid 29531462)
5. Oduwole OO, Li Y, Isomaa VV, et al. 17β-Hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 2004;64:7604-7609 (Pubitemid 39372106)
6. Poutanen M, Isomaa V, Lehto VP, Vihko R. Immunological analysis of 17β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int J Cancer 1992;50:386-390
7. Sasano H, Frost AR, Saitoh R, et al. Aromatase and 17β- hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 1996;81:4042-4046 (Pubitemid 26380415)
8. Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S. Involvement of up-regulation of 17β-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 2001;94:685-689 (Pubitemid 33035688)
9. Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J Steroid Biochem Mol Biol 1995;55:581-587 (Pubitemid 26019342)
10. Miettinen MM, Mustonen MV, Poutanen MH, Isomaa VV, Vihko RK. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J 1996;314:839-845 (Pubitemid 26097745)
11. Gunnarsson C, Ahnstrom M, Kirschner K, et al. Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 2003;22:34-40. (Pubitemid 36152881)
12. Gunnarsson C, Jerevall PL, Hammar K, et al. Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Res Treat 2008;108:35-41.
13. Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 2007;112:700-709
14. Utsumi T, Kobayashi N, Hanada H. Recent perspectives of endocrine therapy for breast cancer. Breast Cancer 2007;14:194-199
15. Rutqvist LE, Johansson H. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 2007;46:133-145 (Pubitemid 46277056)
16. Jansson A, Gunnarsson C, Stal O. Proliferative responses to altered 17β-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocr Relat Cancer 2006;13:875-884
17. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H. 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer 2000;82:518-523 (Pubitemid 30085183)
18. Song D, Liu G, Luu-The V, et al. Expression of aromatase and 17β-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol 2006;101:136-144
19. Pasqualini JR. Differential effects of progestins on breast tissue enzymes. Maturitas 2003;46:S45-54.
20. 2. Mol Endocrinol 2001;15:2093-2105
21. Speirs V, Green AR, Atkin SL. Activity and gene expression of 17β-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. J Steroid Biochem Mol Biol 1998;67:267-274 (Pubitemid 28547095)
22. Speirs V, Walton DS, Hall MC, Atkin SL. In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6. Br J Cancer 1999;81:690-695
23. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003;17:575-588 (Pubitemid 36403572)
24. Kallstrom A-C SR, Ryden L, Gunnarsson C, Nordenskjold B, Stal O. 17-hydroxysteroid dehydrogenase type 1 is a predictive factor in premenopausal hormone receptor positive breast cancer treated with tamoxifen. 30th Annual San Antonio Breast Cancer Symposium; San Antonio; 2007.
25. Kitawaki J, Koshiba H, Ishihara H, Kusuki I, Tsukamoto K, Honjo H. Progesterone induction of 17β-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium. J Clin Endocrinol Metab 2000;85:3292-3296